Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HR68, a derivative of the peroxisome proliferator-activated receptor (PPAR) agonist fenofibric acid, serves as an anticancer agent. It effectively reduces the viability of LN-229 glioblastoma cells, with an IC50 value of 1.17 µM. Notably, HR68 is capable of crossing the blood-brain barrier in temozolomide-resistant orthotopic patient-derived xenograft (PDX) mouse models of glioblastoma.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 35 days | $ 63.00 | |
5 mg | 35 days | $ 220.00 | |
10 mg | 35 days | $ 375.00 | |
50 mg | 35 days | $ 1,400.00 |
Description | HR68, a derivative of the peroxisome proliferator-activated receptor (PPAR) agonist fenofibric acid, serves as an anticancer agent. It effectively reduces the viability of LN-229 glioblastoma cells, with an IC50 value of 1.17 µM. Notably, HR68 is capable of crossing the blood-brain barrier in temozolomide-resistant orthotopic patient-derived xenograft (PDX) mouse models of glioblastoma. |
Synonyms | PP21 |
Molecular Weight | 394.85 |
Formula | C22H19ClN2O3 |
CAS No. | 2454582-64-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Methanol: Soluble
Ethanol: Soluble
Chloroform: Soluble
Acetonitrile: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HR68 2454582-64-8 PP21 inhibitor inhibit